CRISPR Therapeutics AG (CRSP) stock price, news and key stats

About CRISPR Therapeutics AG

Latest CRSP news

• ‘All it will take is one screw-up’: AI groups race to limit bioweapon risks
  FT Companies · Sep 2, 2026

  As artificial intelligence continues to advance, executives and biosecurity experts are increasingly alarmed about the potential for these technologies to be misused in the creation of bioweapons. The rapid development of AI tools capable of generating biological data raises significant concerns about the ease with which individuals could design novel viruses or other harmful pathogens. This has prompted a race among AI groups to implement safeguards and limit the risks associated with these powerful technologies. The implications for markets are profound, particularly in sectors related to biotechnology and pharmaceuticals. Investors are likely to scrutinize companies involved in AI and genetic engineering more closely, assessing their risk management strategies and ethical frameworks. Regulatory bodies may also step up oversight, potentially leading to increased compliance costs and affecting innovation timelines. As the threat of bioweapons looms, the urgency for robust biosecurity measures could reshape investment priorities, with a greater emphasis on companies that prioritize safety and ethical considerations in their AI applications. The situation underscores a critical intersection of technology and public safety, where the stakes are high and the margin for error is slim. Industry leaders are advocating for collaborative efforts to establish guidelines and best practices that can mitigate the risks while still fostering innovation. As these discussions unfold, the market will be watching closely to see how companies navigate this complex landscape and what measures they implement to prevent a potential catastrophe.

• Rat Model Market Outlook Signals Expansion To $2.8 Billion Through 2030
  Market Outlook · Aug 25, 2026

  The rat model market is projected to experience significant growth, reaching an estimated value of $2.8 billion by 2030. This expansion is driven by the increasing demand for advanced preclinical research models in drug development, as well as the rising prevalence of chronic diseases that necessitate extensive research and testing. The use of rat models is particularly favored due to their physiological and genetic similarities to humans, making them valuable for studying various human diseases and testing new therapies. Key factors contributing to this market growth include advancements in genetic engineering techniques, such as CRISPR, which allow for the creation of more precise and relevant animal models. Additionally, the growing emphasis on personalized medicine is pushing researchers to utilize rat models that can better mimic human responses to treatments. As pharmaceutical and biotechnology companies continue to invest in research and development, the demand for reliable and effective animal models is expected to rise, further propelling the market. Market implications suggest that companies involved in the production and supply of rat models may see increased opportunities for collaboration with research institutions and pharmaceutical firms. Moreover, as regulatory bodies emphasize the importance of preclinical testing, the rat model market may benefit from enhanced funding and support, solidifying its role in the broader landscape of biomedical research.

• As China Hunts for Scientific Talent, the US Makes It Easier
  NYT Business · Aug 17, 2026

  In a strategic shift aimed at bolstering its technological and scientific capabilities, the United States has announced measures to simplify the immigration process for foreign talent, particularly in STEM fields. This move comes as China intensifies its efforts to attract top scientists and researchers, creating a competitive landscape for global talent. The U.S. initiative is expected to enhance its appeal to skilled professionals, potentially leading to a significant influx of expertise that could drive innovation and economic growth. The implications for the market are substantial. By streamlining visa processes and providing incentives for foreign researchers, the U.S. aims to secure its position as a leader in technology and innovation. This could result in increased investment in research and development, particularly in sectors such as artificial intelligence, biotechnology, and renewable energy. Conversely, China's aggressive recruitment strategies may lead to a brain drain, as talented individuals weigh their options between the two nations. As both countries vie for supremacy in scientific advancement, the global market may witness shifts in investment patterns and collaborations, influencing various industries and sectors.

• In-vivo Prime Editing Platform Market Outlook Highlights Strategic Opportunities Across The Industry
  Market Outlook · Aug 13, 2026

  The in-vivo prime editing platform market is poised for significant growth, driven by advancements in gene editing technologies and increasing investment in biotechnology research. As the demand for precise genetic modifications rises, the market is expected to expand rapidly, with strategic opportunities emerging for companies that innovate in this space. Analysts project that the market could reach a valuation of several billion dollars within the next five years, fueled by applications in therapeutic development, agriculture, and genetic research. Key players in the industry are focusing on collaborations and partnerships to enhance their capabilities and broaden their product offerings. This trend is likely to lead to a surge in mergers and acquisitions as companies seek to consolidate their positions and leverage complementary technologies. Moreover, regulatory advancements and growing acceptance of gene editing in clinical settings are expected to further accelerate market growth. Investors are advised to closely monitor developments in this sector, as breakthroughs in prime editing could reshape therapeutic approaches to genetic disorders and other diseases, presenting lucrative opportunities for early adopters.

• Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial
  CNBC · Apr 27, 2026

  Intellia Therapeutics announced that its CRISPR-based therapy lonvoguran ziclumeran (lonvo-z) met primary and secondary endpoints in the Phase 3 HAELO trial for hereditary angioedema (HAE), demonstrating a statistically significant and clinically meaningful reduction in monthly swelling attacks. The trial enrolled patients globally and completed enrollment just nine months after first dosing, with topline data expected in the first half of 2026. Despite the clinical success — widely viewed as a pivotal validation for in vivo CRISPR therapeutics — Intellia’s shares fell sharply on the news, reflecting investor concerns over pricing, commercial scalability, and competitive dynamics in the rare disease space. Market reaction underscores persistent skepticism around near-term revenue visibility for gene-editing therapies, even with robust efficacy signals. The outcome reinforces CRISPR’s therapeutic viability beyond ex vivo applications (e.g., sickle cell disease), establishing lonvo-z as the first in vivo CRISPR candidate to reach Phase 3 completion for a non-oncologic, non-hematologic indication. Regulatory pathways remain uncertain: while the FDA has granted lonvo-z Fast Track and Orphan Drug designations, full approval will hinge on durability of response, long-term safety monitoring, and risk-benefit assessment across diverse patient subgroups. Broader implications extend to the biotech sector’s valuation framework, where clinical de-risking is increasingly decoupled from near-term equity performance amid tightening capital markets and heightened scrutiny of commercial execution. From a market structure perspective, the result may catalyze renewed interest in CRISPR platform companies and gene-editing enablers, though sentiment remains bifurcated between technical validation and commercial realism. Equity underperformance highlights how macro headwinds — including rising cost-of-capital and biotech funding constraints — continue to compress valuations for assets lacking clear reimbursement pathways or established commercial infrastructure. Investors are now focusing on whether Intellia can secure partnerships, accelerate payer engagement, and demonstrate durable suppression of HAE attacks beyond 12 months — all critical inputs for FDA label expansion and global health authority submissions.